Several studies have focused on the relationships between the expression of
extracellular matrix metalloproteinase inducer (EMMPRIN) and the prognosis of patients with malignant
tumors. However, few of these have investigated the expression of
EMMPRIN in
osteosarcoma. We examined expression levels of
EMMPRIN immunohistochemically in 53 cases of high-grade
osteosarcoma of the extremities and analyzed the correlation of its expression with patient prognosis. The correlation between
matrix metalloproteinases (
MMPs) and
EMMPRIN expression and the prognostic value of co-expression were also analyzed. Staining positivity for
EMMPRIN was negative in 7 cases, low in 17, moderate in 19, and strong in 10. The overall and disease-free survivals (OS and DFS) in patients with higher
EMMPRIN expression (strong-moderate) were significantly lower than those in the lower (weak-negative) group (0.037 and 0.024, respectively). In multivariate analysis, age (P=0.004), location (P=0.046), and
EMMPRIN expression (P=0.038) were significant prognostic factors for overall survival.
EMMPRIN expression (P=0.024) was also a significant prognostic factor for disease-free survival. Co-expression analyses of
EMMPRIN and
MMPs revealed that strong co-expression of
EMMPRIN and membrane-type 1 (MT1)-MMP had a poor prognostic value (P=0.056 for DFS, P=0.006 for OS).
EMMPRIN expression and co-expression with
MMPs well predict the prognosis of patients with extremity
osteosarcoma, making
EMMPRIN a possible therapeutic target in these patients.